SCHEMBL6017737

SCHEMBL6017737

Cc1ccc(CNC(=O)c2nc(-c3c(F)cccc3F)n(C)c(=O)c2O)cc1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.44
CCR1 P32246 1/20 0.44
KCNQ1 P51787 1/20 0.44
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
MMP13 P45452 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AADAT Q8N5Z0 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CALCA P06881 1/20 0.38
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
SCD O00767 1/20 0.38
LIPG Q9Y5X9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017779 0.91 KCNE1 (0.42) KCNE1CCR1KCNQ1ADORA2AADORA1
SCHEMBL6017839 0.91 SCD (0.46) KCNE1CCR1KCNQ1ADORA2AADORA1
SCHEMBL6017708 0.89 KCNE1 (0.48) KCNE1CCR1KCNQ1SMN1; SMN2AADAT
SCHEMBL6017627 0.89 KCNE1 (0.54) KCNE1CCR1KCNQ1SMN1; SMN2AADAT
SCHEMBL6018223 0.88 CNR1 (0.48) KCNE1CCR1KCNQ1MEN1KMT2A
SCHEMBL6018572 0.87 KMT2A (0.49) KCNE1CCR1KCNQ1SMN1; SMN2MEN1
SCHEMBL6018064 0.87 KCNE1 (0.44) KCNE1CCR1KCNQ1ADORA2AADORA1
SCHEMBL6017934 0.86 TSHR (0.46) KCNE1CCR1KCNQ1ADORA2ASMN1; SMN2
SCHEMBL6017701 0.86 ALDH1A1 (0.52) MMP13SMN1; SMN2MEN1KMT2A
SCHEMBL6017795 0.85 MMP1 (0.50) KCNE1CCR1KCNQ1MMP13MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.